Nvidia, AMD to pay 15% of China chip sales revenue to US govt- FT
HACKENSACK, NJ - Champions Oncology (NASDAQ:CSBR) announced on Tuesday the commercial launch of its radiopharmaceutical services platform after expanding its radioactive materials license and completing radiochemistry infrastructure.
The company has screened more than 30 patient-derived xenograft (PDX) models in collaboration with pharmaceutical and biotech partners, according to a press release statement.
The platform offers integrated radiopharmaceutical workflows combining in vitro, ex-vivo biodistribution, and therapeutic efficacy studies across multiple isotopes. Champions’ updated license now includes support for ten isotopes: Lu-177, Ac-225, In-111, Cu-67, Y-90, Pb-212, At-211 Tb-161, Cu-64, and Zr-89.
"Radiopharmaceuticals represent one of the most exciting frontiers in precision oncology," said Mike Ritchie, Chief Commercial Officer at Champions Oncology. "By combining advanced radiochemistry infrastructure with the world’s most deeply characterized PDX bank, we’re helping our clients generate meaningful, translational data."
The company stated that the platform enables drug developers to evaluate radiolabeled agents in clinically relevant systems, supporting various study designs including radioligand therapy, antibody radionuclide conjugates, and theranostic approaches.
Champions Oncology describes itself as a preclinical and clinical research services provider offering oncology R&D solutions to biopharma organizations.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.